JP2012501959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501959A5 JP2012501959A5 JP2010523608A JP2010523608A JP2012501959A5 JP 2012501959 A5 JP2012501959 A5 JP 2012501959A5 JP 2010523608 A JP2010523608 A JP 2010523608A JP 2010523608 A JP2010523608 A JP 2010523608A JP 2012501959 A5 JP2012501959 A5 JP 2012501959A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- immunogenic composition
- antigens
- ypo0499
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 631
- 102000036639 antigens Human genes 0.000 claims description 631
- 108091007433 antigens Proteins 0.000 claims description 631
- 230000002163 immunogen Effects 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 75
- 230000028993 immune response Effects 0.000 claims description 29
- 241000124008 Mammalia Species 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 101100294224 Yersinia pestis nlpI gene Proteins 0.000 claims description 9
- 101100493693 Yersinia pestis bamC gene Proteins 0.000 claims description 6
- 101100116909 Yersinia pestis djlA gene Proteins 0.000 claims description 6
- 101100421109 Yersinia pestis secM gene Proteins 0.000 claims description 6
- 101100381447 Yersinia pestis bamA gene Proteins 0.000 claims description 4
- 101100440427 Yersinia pestis coaE gene Proteins 0.000 claims description 4
- 101100064180 Yersinia pestis dsbA gene Proteins 0.000 claims description 4
- 101100281900 Yersinia pestis fyuA gene Proteins 0.000 claims description 4
- 101100220525 Yersinia pestis groEL gene Proteins 0.000 claims description 4
- 101100126385 Yersinia pestis ispD gene Proteins 0.000 claims description 4
- 101100188657 Yersinia pestis ompA gene Proteins 0.000 claims description 4
- 101100060882 Yersinia pestis pla gene Proteins 0.000 claims description 4
- 101100475179 Yersinia pestis rpsC gene Proteins 0.000 claims description 4
- 101100093726 Yersinia pestis rpsD gene Proteins 0.000 claims description 4
- 101100365859 Yersinia pestis skp gene Proteins 0.000 claims description 4
- 101100478915 Yersinia pestis surA gene Proteins 0.000 claims description 4
- 101100118435 Yersinia pestis tufA gene Proteins 0.000 claims description 4
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 101100170819 Yersinia pestis dnaK gene Proteins 0.000 claims description 3
- 101100472136 Yersinia pestis rplI gene Proteins 0.000 claims description 3
- 101100207359 Yersinia pestis tpx gene Proteins 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 16
- 238000003491 array Methods 0.000 claims 1
- 101100393774 Yersinia pestis hemL gene Proteins 0.000 description 3
- 101100256513 Yersinia pestis secB gene Proteins 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0717187.9A GB0717187D0 (en) | 2007-09-04 | 2007-09-04 | Compositions comprising yersinia pestis antigens |
| PCT/IB2008/003081 WO2009031043A2 (en) | 2007-09-04 | 2008-09-04 | Compositions comprising yersinia pestis antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012501959A JP2012501959A (ja) | 2012-01-26 |
| JP2012501959A5 true JP2012501959A5 (OSRAM) | 2012-10-11 |
Family
ID=38640215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523608A Pending JP2012501959A (ja) | 2007-09-04 | 2008-09-04 | Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ抗原を含む組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100183674A1 (OSRAM) |
| EP (1) | EP2205274A2 (OSRAM) |
| JP (1) | JP2012501959A (OSRAM) |
| AU (1) | AU2008294413A1 (OSRAM) |
| CA (1) | CA2698360A1 (OSRAM) |
| GB (1) | GB0717187D0 (OSRAM) |
| WO (1) | WO2009031043A2 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| HRP20161352T1 (hr) | 2010-07-06 | 2016-12-02 | Glaxosmithkline Biologicals Sa | Čestice nalik na virione za unos samoreplicirajućih molekula rna |
| CN103384515B (zh) | 2010-08-31 | 2017-02-15 | 诺华有限公司 | 适用于脂质体递送编码蛋白质的rna的脂质 |
| DK4226941T3 (da) | 2010-08-31 | 2024-12-02 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til levering af immunogen-kodende rna |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| WO2012103421A1 (en) | 2011-01-27 | 2012-08-02 | Novartis Ag | Adjuvant nanoemulsions with crystallisation inhibitors |
| ES2785108T3 (es) | 2011-03-24 | 2020-10-05 | Glaxosmithkline Biologicals Sa | Nanoemulsiones adyuvantes con fosfolípidos |
| CN103764121A (zh) | 2011-07-06 | 2014-04-30 | 诺华股份有限公司 | 用于递送rna分子的具有有用n:p比的脂质体 |
| US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| US20140255472A1 (en) | 2011-08-31 | 2014-09-11 | Andrew Geall | Pegylated liposomes for delivery of immunogen-encoding rna |
| EP2897635A1 (en) | 2012-09-18 | 2015-07-29 | Novartis AG | Outer membrane vesicles |
| EA201891018A1 (ru) | 2013-03-08 | 2018-09-28 | Новартис Аг | Липиды и липидные композиции для доставки активных агентов |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| EP3083579B1 (en) | 2013-12-19 | 2022-01-26 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| EP3188760B1 (en) | 2014-09-05 | 2023-12-06 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| AU2021360494A1 (en) | 2020-10-14 | 2023-05-18 | George Mason Research Foundation, Inc. | Ionizable lipids and methods of manufacture and use thereof |
| EP4387596A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| EP4387597A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0815235T3 (da) * | 1995-03-13 | 2003-04-22 | Secr Defence | Vacciner mod pest |
| US7776336B2 (en) * | 2005-10-25 | 2010-08-17 | Novartis Vaccines And Diagnostics Srl | Compositions comprising Yersinia pestis antigens |
-
2007
- 2007-09-04 GB GBGB0717187.9A patent/GB0717187D0/en not_active Ceased
-
2008
- 2008-09-04 WO PCT/IB2008/003081 patent/WO2009031043A2/en not_active Ceased
- 2008-09-04 US US12/733,488 patent/US20100183674A1/en not_active Abandoned
- 2008-09-04 EP EP08829437A patent/EP2205274A2/en not_active Withdrawn
- 2008-09-04 CA CA2698360A patent/CA2698360A1/en not_active Abandoned
- 2008-09-04 JP JP2010523608A patent/JP2012501959A/ja active Pending
- 2008-09-04 AU AU2008294413A patent/AU2008294413A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501959A5 (OSRAM) | ||
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2010500399A5 (OSRAM) | ||
| CA2187083C (fr) | Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation | |
| JP2009515831A5 (OSRAM) | ||
| JP2008530245A5 (OSRAM) | ||
| JP2007505033A5 (OSRAM) | ||
| JP2018509935A5 (OSRAM) | ||
| JP2015509707A5 (OSRAM) | ||
| JP2012523246A5 (OSRAM) | ||
| CN105792842A (zh) | 埃巴病毒疫苗 | |
| JP2014507146A5 (OSRAM) | ||
| JP2015529678A5 (OSRAM) | ||
| CA2789483A1 (en) | Novel hiv-1 envelope glycoprotein | |
| JP2013504556A5 (OSRAM) | ||
| JP2015505309A5 (OSRAM) | ||
| JP2012525410A5 (OSRAM) | ||
| JP2009520758A5 (OSRAM) | ||
| JP2013545448A5 (OSRAM) | ||
| Li et al. | Surface display of classical swine fever virus E2 glycoprotein on gram-positive enhancer matrix (GEM) particles via the SpyTag/SpyCatcher system | |
| JP2018516926A (ja) | ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物 | |
| EP3715359A1 (en) | Cd4 helper t cell epitope fusion peptide and vaccine therewith | |
| WO2022127825A1 (zh) | 针对新型冠状病毒感染的疫苗组合物 | |
| ES2236718T3 (es) | Proteina portadora de efecto adyuvante, complejo inmunogenico que la contiene, su procedimiento de preparacion, secuencia nucleotidica y vacuna. | |
| Valmori et al. | Induction of a cytotoxic T cell response by co‐injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): Further enhancement by pre‐injection of IFA alone |